[Report] Molecular Targeted Cancer Therapies Market Research, Trends, Analysis TOC

ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Scope of analysis
- Datamonitor insight into the molecular targeted therapies market
- Related reports
- Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
  - Late-phase pipeline molecular targeted cancer therapies
  - Phase II pipeline molecular targeted cancer therapies
  - Phase I pipeline molecular targeted cancer therapies
- Pipeline by developmental phase and class of drug
  - There are 329 different MTTs in the clinical development pipeline
    - The cell cycle and apoptosis targeted agents make up the largest number of MTTs in the pipeline
  - Segmentation of drugs by developmental phase reflects attrition rate of drug development in the oncology market
    - Targeted therapy remains a promising anticancer drug development strategy
    - Developmental agents by phase for each class
- Pipeline by indication
  - Pipeline MTTs are being investigated in 29 different cancers
    - The ' big four' tumor types are the most popular indications for development
- Pipeline by mode of action
  - Pipeline products are directed against a huge variety and combination of molecular targets
  - The VEGF/VEGFR family remains the focus of development for MTTs
- Pipeline by company
  - There are 175 different companies developing targeted therapies
    - Developmental pipeline dominated by small pharma/biotech players
  - There are 19 companies with MTT products in late-phase development
  - Top three companies in terms of number of pipeline MTT products are Pfizer, AstraZeneca and Novartis
    - Pfizer - 21 MTT pipeline products
    - AstraZeneca - 15 MTT pipeline products
    - Novartis - 12 MTT pipeline products
- Key metrics
- Datamonitor pipeline assessment summary
CHAPTER 3 CURRENT MARKET STATUS & PIPELINE CLASSIFICATION
- Targeted therapies overview
  - The development of molecular targeted therapies
    - Current therapies are less cancer cell-specific
    - The strategy is to target the specific survival factors of a tumor
    - Key issue is the identification of targets unique to cancer cells
- Market definition
  - L1X3 - Antineoplastic monoclonal antibodies
  - L1X9 - All other antineoplastics
- Current market status
- Classification of pipeline products
  - Angiogenesis inhibitors
    - Angiogenesis as a normal biological process
    - Angiogenesis is known to be aberrant in tumor cell proliferation
    - Angiogenesis inhibitors as viable antitumor agents can target a number of pathways
    - At present, only one angiogenesis inhibitor exists on the market
  - Single-target signal transduction inhibitors
    - A plethora of potential targets exist along the signaling cascade
    - Several signal transduction inhibitors have reached the market, bringing with them their own sets of issues for consideration
  - Multi-targeted inhibitors
    - Multi-targeted inhibitors have certain advantages over single targeted agents
    - Approval of three multi-targeted inhibitors
  - Cell cycle and apoptosis targeted inhibitors
    - Only one cell cycle inhibitor has entered Phase III
    - Cell death can be induced via a number of different pathways
    - To date, only one apoptosis stimulator has reached the market
  - Epigenetic modulators
    - Despite relative immaturity of development in this class of drugs, the potential to enhance current therapies exists
  - Immunomodulatory and immunoconjugated therapeutics
    - Antibody-based technologies are an effective anticancer approach
- Oncology clinical trial design
  - Patient selection
    - Increasingly significant in the era of targeted treatment
  - Clinical trial duration
    - Sufficient follow-up is necessary to establish true clinical benefit
  - The advent of novel therapies
    - Diversity of targeted therapies will require an evolution in clinical trial design
  - Clinical trial endpoints in oncology
    - Most oncology clinical trials designate multiple endpoints
    - Survival
    - Quality of life
    - Tumor response rates
    - Toxicity
    - Time to tumor progression
CHAPTER 4 PIPELINE ANGIOGENESIS INHIBITORS ANALYSIS & FORECASTS
- Overview of angiogenesis inhibitors
  - Pipeline summary
    - Late-phase pipeline of angiogenesis inhibitors
    - Phase II pipeline of angiogenesis inhibitors
    - Phase I pipeline of angiogenesis inhibitors
  - Comparative forecasts
  - Definition of current comparator therapy
    - Avastin (Bevacizumab; Genentech/Roche/Chugai)
- Aflibercept (VEGF-Trap; Sanofi Aventis/Regeneron)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Interim Phase II results for aflibercept in ovarian cancer
    - Interim Phase II results for aflibercept in NSCLC
    - Aflibercept demonstrates similar side effects to Avastin
  - Datamonitor comments
    - Fierce competition with Avastin in the wider cancer market
    - Presence in oncology field will aid commercialization of aflibercept
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Pazopanib (GW786034; GlaxoSmithKline)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Pazopanib as a possible second-line monotherapy treatment for metastatic RCC
    - Co-administration with Tykerb may alter the pharmacokinetics of pazopanib - Phase III studies planned
    - Pazopanib showing applicability across a broad range of solid tumor types
  - Datamonitor comments
    - Initial approval in RCC will force pazopanib to compete against the already approved Sutent and Nexavar
    - Extensive parallel development program planned
    - Tykerb may well enhance the success of pazopanib but at what price?
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Recentin (Cediranib, AZD2171; AstraZeneca)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - AstraZeneca targets first-line CRC
    - Recentin has potential in NSCLC in combination with standard chemotherapy regimens
    - Phase III study planned for Recentin in glioma
  - Datamonitor comments
    - As a potentially more potent inhibitor of angiogenesis, and given its formulation, Recentin' s future may be highly promising
    - Phase III studies in CRC are high-risk while development in glioma may offer a quicker route to market
    - AstraZeneca' s strength in the oncology market will be key in Recentin' s success
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 5 PIPELINE SINGLE-TARGET SIGNAL TRANSDUCTION INHIBITORS ANALYSIS & FORECASTS
- Overview of single-target signal transduction inhibitors
  - Pipeline summary
    - Late-phase pipeline of single-target signal transduction inhibitors
    - Phase II pipeline of single-target signal transduction inhibitors
    - Phase I pipeline of single-target signal transduction inhibitors
  - Comparative forecasts
  - Definition of current comparator therapy
    - Gleevec (Imatinib; Novartis)
- Certican (Everolimus, RAD-001; Novartis)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Certican may be a promising addition to the treatment of neuroendocrine tumors
    - Certican is also showing applicability in some of the more common tumor types
  - Datamonitor comments
    - Approval as an anticancer therapy will enable Certican to achieve a significantly higher level of sales
    - NET a good place to start
    - Novartis is an ideal backer for the drug
    - Certican may face stiff competition from Torisel
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Sarasar (Lonafarnib; Schering-Plough)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Main focus of Sarasar is development in MDS, where greatest antitumor activity is shown
    - Farnesyl transferase inhibitors predominately in hematological disorders
    - Lack of efficacy has led to termination of pivotal Phase III trial in NSCLC
    - Lack of clinical data makes it difficult to judge Sarasar' s potential in breast cancer
    - Benefit shown in advanced head and neck cancer, although no further trials have been announced
    - Mild toxicity in the majority of patients, although grade 3 events do occur
  - Datamonitor comments
    - Sarasar' s chances for approval will be delayed beyond 2007
    - Sarasar racing against Johnson & Johnson' s Zarnestra as the first farnesyl transferase inhibitor to reach the market
    - Presence in oncology market will aid commercialization of Sarasar
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- TheraCIM (Nimotuzumab; YM Bioscience)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Phase III underway for pediatric pontine (brain stem) glioma
    - Phase II pediatric trial demonstrated activity
  - Datamonitor comments
    - Phase III trial results required to verify the efficacy of this agent
    - YM Biosciences look to broaden TheraCIM' s horizons
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Xinlay (Atrasentan; Abbott Laboratories)
  - Drug overview
    - Xinlay' s target receptor plays a key role in cancer cell proliferation
  - Key historical events
  - Clinical trial data
    - FDA do not approve Xinlay for prostate cancer
    - Not the end of the road for Xinlay with new Phase III trial now underway
  - Datamonitor comments
    - Despite its rejection by the FDA, Xinlay' s future may still be promising
    - Abbott' s favorable position in the prostate cancer market will be invaluable
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zalutumumab (HuMax-EGFR; Genmab)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - With Fast Track status granted, SCCHN offers promise as a lead indication for zalutumumab
  - Datamonitor comments
    - A head-to-head study against Erbitux could work in zalutumumab' s favor
    - Zalutumumab will need to be competitively priced
    - Zalutumumab may also have to compete with Tarceva and Iressa
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zarnestra (Tipifarnib; Johnson & Johnson)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Following rejection of NDA, the FDA requires Phase III data for Zarnestra in AML before regulatory approval can be considered
    - Results from Phase III studies have yet to be announced
    - Zarnestra has demonstrated a favorable profile in Phase II studies
    - Single-agent Zarnestra demonstrates antitumor activity in relapsed/refractory aggressive NHL
    - Zarnestra holding promise in juvenile myelomonocytic leukemia
    - Following modest activity in brain cancer, further trials have been initiated
    - Negative Phase III trial results cause termination of development in pancreatic and colorectal cancer
  - Datamonitor comments
    - Schering-Plough' s Sarasar catching up with Zarnestra as the first farnesyl transferase inhibitor to reach the market
    - Johnson & Johnson limiting Zarnestra' s target population in the short term
    - Johnson & Johnson' s experience will be invaluable to Zarnestra
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 6 PIPELINE MULTI-TARGETED INHIBITORS ANALYSIS & FORECASTS
- Overview of multi-targeted inhibitors
  - Pipeline summary
    - Late-phase pipeline of multi-targeted inhibitors
    - Phase II pipeline of multi-targeted inhibitors
    - Phase I pipeline of multi-targeted inhibitors
  - Comparative forecasts
  - Definition of current comparator therapy
    - Gleevec (Imatinib; Novartis)
- Tasigna (Nilotinib, AMN-107; Novartis)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Tasigna awaiting approval in the US, the EU and Japan for Gleevec-resistant CML
    - Promising Phase II data reported
    - Tasigna appears effective in CML patients who have failed or are intolerant to both Gleevec and Sprycel
    - Only one Bcr-Abl mutation is insensitive to Tasigna
    - Tasigna shows promise for Gleevec-resistant metastatic GIST patients
  - Datamonitor comments
    - Tasigna ready to challenge Bristol-Myers Squibb' s already approved Sprycel
    - Novartis looking to expand its leading role in the CML therapy market
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Axitinib (AG-13736; Pfizer)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Phase III trial warranted in pancreatic cancer following a 26% reduction in the risk of death when axitinib is added to Gemzar - Phase II results
    - Axitinib demonstrates impressive activity in thyroid cancer. Phase III trial yet to start
    - Axitinib also making encouraging progress in other popular tumor types
  - Datamonitor comments
    - A similar response rate to Tarceva in pancreatic cancer means approval will be likely
    - Axitinib will enjoy the global presence and unparalleled marketing strength Pfizer can offer
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Ceflatonin (Myelostat; ChemGenex Pharmaceuticals)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Ceflatonin aims to restore Gleevec sensitivity in CML patients
    - ChemGenex looking to expand Ceflatonin into the AML/APL market
  - Datamonitor comments
    - Despite convincing clinical benefit, Ceflatonin will face strong competition from Bristol-Myers Squibb' s Sprycel and Novartis' s Tasigna
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Enzastaurin (LY317615; Eli Lilly)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Enzastaurin looking to make its mark in the B-cell lymphoma market
    - Enzastaurin holding promise as a maintenance therapy in mantle cell lymphoma
    - Despite discontinuation of a Phase III trial in Glioma, Eli Lilly has initiated 20 additional clinical trials
  - Datamonitor comments
    - Eli Lilly adopt a risky strategy for enzastaurin in DLBCL
    - Termination of Phase III trial for enzastaurin in glioma may hamper its potential in other indications
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Lestaurtinib (CEP-701; Cephalon)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Lestaurtinib emerging as a promising agent for AML patients harboring Flt-3 activating mutations
  - Datamonitor comments
    - Lestaurtinib may be the first in its class to reach the market
    - Cephalon' s recent acquisition of Trisenox will provide valuable experience of the leukemia market
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zactima (Vandetanib, ZD6474; AstraZeneca)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Zactima granted Orphan Drug designation and Fast Track status for Thyroid cancer
    - Multiple Phase III trials for Zactima underway in NSCLC
    - Zactima fails to demonstrate efficacy as a maintenance therapy for SCLC
  - Datamonitor comments
    - Zactima set to enjoy a monopoly of thyroid cancer niche market
    - Zactima being pushed through the clinical development process for NSCLC
    - Zactima offers product differentiation with unique multi-targeted characteristics
    - AstraZeneca' s strength in the oncology market will be key in Zactima' s success
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 7 PIPELINE CELL CYCLE AND APOPTOSIS TARGETED AGENTS ANALYSIS & FORECASTS
- Overview of cell cycle and apoptosis targeted agents
  - Pipeline summary
    - Late-phase pipeline of cell cycle and apoptosis targeted agents
    - Phase II pipeline of cell cycle and apoptosis targeted agents
    - Phase I pipeline of cell cycle and apoptosis targeted agents
  - Comparative forecasts
  - Definition of current comparator therapy
    - Velcade (Bortezomib; Millennium Pharmaceuticals)
- Alvocidib (Flavopiridol; Sanofi-Aventis)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Continuous infusion dosing schedules fail to demonstrate clinical activity
    - Modified dosing regimen drives further development in CLL
  - Datamonitor comments
    - Given alvocidib' s checkered history, Sanofi-Aventis may face an uphill struggle communicating the drug' s potential
    - Alvocidib may show more promise as part of a combination regimen
    - Presence in oncology field will aid commercialization of alvocidib
- Genasense (Oblimersen; Genta)
  - Drug overview
  - Key historical events
  - Datamonitor comments
    - Approval of Genasense is looking increasingly unlikely
    - Termination of agreement with Sanofi-Aventis is a major setback for Genta
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Phenoxodiol (Novogen)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - The OVATURE trials
    - The combination of phenoxodiol and cisplatin is particularly effective in ovarian cancer
  - Datamonitor comments
    - Toxicity will be the key factor for phenoxodiol' s success
    - Sanofi-Aventis as a marketing partner?
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 8 PIPELINE IMMUNOMODULATORY AND IMMUNOCONJUGATED THERAPEUTICS ANALYSIS & FORECASTS
- Overview of immunomodulatory and immunoconjugated therapeutics
  - Pipeline summary
    - Late-phase pipeline of immunomodulatory and immunoconjugated therapeutics
    - Phase II pipeline of immunomodulatory and immunoconjugated therapeutics
    - Phase I pipeline of immunomodulatory and immunoconjugated therapeutics
  - Comparative forecasts
  - Definition of current comparator therapy
    - Rituxan (Rituximab; Biogen Idec/Genentech/Roche)
- Galiximab (Anti-CD80 MAb; Biogen Idec)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Randomized Phase III trial will compare survival of galiximab plus Rituxan with Rituxan alone in relapsed/refractory follicular NHL patients
    - Phase II results show galiximab and Rituxan can be safely combined and can produce promising response rates in follicular NHL patients
  - Datamonitor comments
    - Biogen Idec in a strong position to successfully market galiximab alone
    - Biogen-Idec will need to effectively demonstrate the value of a combination of galiximab and Rituxan to payers
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Lumiliximab (Anti-CD23 MAb; Biogen Idec)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - The addition of lumiliximab to the FCR regimen may produce a higher response rate without additional toxicity
  - Datamonitor comments
    - Lumiliximab on course to become an established addition to the standard treatment for CLL
    - Biogen Idec should look to investigate Lumiliximab as a maintenance therapy
    - Cluster of Differentiation (CD) drugs have become Biogen Idec' s specialty
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Ofatumumab (HuMax-CD20; Genmab/GlaxoSmithKline)
  - Drug overview
    - Genmab hoping ofatumumab will demonstrate a preferred efficacy profile over Rituxan in the clinic
  - Key historical events
  - Clinical trial data
    - Ofatumumab receives Fast Track status for CLL and enters a Phase III trial
    - Genmab initiates a pivotal Phase III trial in follicular NHL
  - Datamonitor comments
    - Ofatumumab may offer hope for Rituxan-insensitive patients
    - Approval of other MAbs being developed by Biogen Idec for NHL and CLL may restrict ofatumumab' s potential even further
    - GlaxoSmithKline will offer invaluable experience to Genmab and aid commercialization of ofatumumab
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Proxinium/Vicinium (VB4-845; Viventia Biotech)
  - Drug overview
    - An ' armed' antibody for the potential treatment of head and neck, and bladder cancer
  - Key historical events
  - Clinical trial data
    - Proxinium shows a good safety profile and preliminary evidence of clinical efficacy in Phase I trials in head and neck cancer
    - Vicinium also making headway in bladder cancer
  - Datamonitor comments
    - The requirement for EpCAM expression may limit Proxinium' s uptake
    - Proxinium will have to compete with Erbitux
    - Viventia should look to investigate Proxinium in combination with radiotherapy
    - BCG failure creates a commercial opportunity for Vicinium
    - Vicinium may face competitive pressure from novel intravesical chemotherapies in the near future
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Rencarex (WX-G250; Wilex)
  - Drug overview
    - MN/CA IX Antigen - A highly specific tumor target
    - Mode of Action of Rencarex - ADCC
  - Key historical events
  - Clinical trial data
    - Completed Phase I & II trials for metastatic RCC
    - In patients responding to treatment, Rencarex monotherapy improves survival
    - The combination with IFN is well-tolerated and of clinical benefit in metastatic RCC
  - Datamonitor comments
    - The high recurrence rate for RCC creates a commercial opportunity
    - Rencarex may face a number of hurdles
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zanolimumab (HuMax-CD4; Genmab)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Zanolimumab' s Orphan Drug and Fast Track status reflects the high unmet needs in CTCL
    - Zanolimumab may also hold promise for PTCL patients
  - Datamonitor comments
    - The T-cell lymphoma market offers zanolimumab a limited commercial potential
    - Depletion of CD4+ T-cells by zanolimumab may render the patient susceptible to opportunistic infections
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 9 PIPELINE EPIGENETIC MODULATORS ANALYSIS & FORECASTS
- Overview of epigenetic modulators
  - Pipeline summary
    - Late-phase pipeline of epigenetic modulators
    - Phase II pipeline of epigenetic modulators
    - Phase I pipeline of epigenetic modulators
APPENDIX
- List of tables
- List of figures
- Methodology
  - Datamonitor forecast methodology
    - Epidemiology forecasts
    - Product forecasts
  - Datamonitor drug assessment summary
- Abbreviations
- Contributing experts
- Bibliography
- About Datamonitor
  - About Datamonitor Healthcare
- Datamonitor Healthcare' s therapy area capabilities
  - About the Disease analysis team
  - Disclaimer
- List of Tables
  - Table 1: Late-phase pipeline molecular targeted cancer therapies, 2007
  - Table 2: Phase II pipeline molecular targeted cancer therapies, 2007
  - Table 3: Phase I pipeline molecular targeted cancer therapies, 2007
  - Table 4: Pipeline molecular targeted therapies by development phase and class of drug, 2007
  - Table 5: Pipeline molecular targeted therapies by indication, 2007
  - Table 6: Potential anticancer molecular targets being exploited by only one candidate in the clinical development pipeline, 2007
  - Table 7: Potential anticancer molecular targets being exploited by two candidates in the clinical development pipeline, 2007
  - Table 8: Potential anticancer molecular targets being exploited by three candidates in the clinical development pipeline, 2007
  - Table 9: Pfizer' s marketed cancer portfolio, 2007
  - Table 10: Pfizer' s molecular targeted cancer therapies pipeline, 2007
  - Table 11: AstraZeneca' s marketed cancer portfolio, 2007
  - Table 12: AstraZeneca' s molecular targeted cancer therapies pipeline, 2007
  - Table 13: Novartis' s marketed cancer portfolio, 2007
  - Table 14: Novartis' s molecular targeted cancer therapies pipeline, 2007
  - Table 15: Late-phase pipeline molecular targeted therapy products sales forecasts in the seven major markets ($m), 2007-2016
  - Table 16: Currently approved molecular targeted cancer therapies, 2007
  - Table 17: Examples of naturally occurring angiogenesis stimulators
  - Table 18: Recently approved multi-targeted inhibitors, 2007
  - Table 19: Late-phase pipeline angiogenesis inhibitors, 2007
  - Table 20: Phase II pipeline angiogenesis inhibitors, 2007
  - Table 21: Phase I pipeline angiogenesis inhibitors, 2007
  - Table 22: Forecasting assumptions for late-phase angiogenesis inhibitors in the seven major pharmaceutical markets, 2007 (1 of 2)
  - Table 23: Forecasting assumptions for late-phase angiogenesis inhibitors in the seven major pharmaceutical markets, 2007 (2 of 2)
  - Table 24: Avastin: Key facts
  - Table 25: Aflibercept: Key historical events
  - Table 26: Ongoing clinical trials involving aflibercept, 2007
  - Table 27: Interim Phase II results for aflibercept in NSCLC
  - Table 28: Forecasting assumptions for aflibercept in the seven major pharmaceutical markets, 2007
  - Table 29: Aflibercept 7MM sales forecast in second-line ovarian cancer, second-line NSCLC and second-line HRPC ($m), 2007-2016
  - Table 30: Pazopanib: Key historical events
  - Table 31: Ongoing clinical trials involving pazopanib, 2007
  - Table 32: Phase II interim analysis for pazopanib monotherapy in second-line RCC at 12 weeks
  - Table 33: Phase II interim analysis for pazopanib monotherapy in relapsed soft tissue sarcoma at 12 weeks
  - Table 34: Phase II interim analysis for pazopanib monotherapy in high-risk relapsed ovarian cancer at 12 weeks
  - Table 35: Forecasting assumptions for pazopanib in the seven major pharmaceutical markets, 2007
  - Table 36: Pazopanib 7MM sales forecast in first/second-line RCC and second-line Her2+ breast cancer ($m), 2007-2016
  - Table 37: Recentin: Key historical events
  - Table 38: Ongoing clinical trials involving Recentin, 2007
  - Table 39: Phase I results of Recentin plus standard chemotherapy in NSCLC
  - Table 40: Forecasting assumptions for Recentin in the seven major pharmaceutical markets, 2007
  - Table 41: Recentin 7MM sales forecast in first-line NSCLC, first-line CRC and recurrent/ progressive glioma ($m), 2007-2016
  - Table 42: Late-phase pipeline single-target signal transduction inhibitors, 2007
  - Table 43: Phase II pipeline single-target signal transduction inhibitors, 2007
  - Table 44: Phase I pipeline single-target signal transduction inhibitors, 2007
  - Table 45: Forecasting assumptions for late-phase single-target signal transduction inhibitors in the seven major pharmaceutical markets, 2007 (1 of 3)
  - Table 46: Forecasting assumptions for late-phase single-target signal transduction inhibitors in the seven major pharmaceutical markets, 2007 (2 of 3)
  - Table 47: Forecasting assumptions for late-phase single-target signal transduction inhibitors in the seven major pharmaceutical markets, 2007 (3 of 3)
  - Table 48: Gleevec: Key facts
  - Table 49: Certican: Key historical events
  - Table 50: Ongoing clinical trials involving Certican, 2007
  - Table 51: Phase II study results for Certican plus octreotide in NET
  - Table 52: Interim Phase II results of Certican monotherapy in metastatic RCC
  - Table 53: Interim Phase II results of Certican monotherapy in lymphoma
  - Table 54: Forecasting assumptions for Certican in the seven major pharmaceutical markets, 2007
  - Table 55: Certican 7MM sales forecast in second-line NET, second-line RCC, salvage therapy CRC and second-line GIST ($m), 2007-2016
  - Table 56: Sarasar: Key historical events
  - Table 57: Ongoing clinical trials involving Sarasar, 2007
  - Table 58: Phase I/II study results of Sarasar monotherapy in advanced MDS and CMML (1 of 2)
  - Table 59: Phase I/II study results of Sarasar monotherapy in advanced MDS and CMML (2 of 2)
  - Table 60: Phase II results of Sarasar in Head and Neck cancer
  - Table 61: Forecasting assumptions for Sarasar in the seven major pharmaceutical markets, 2007
  - Table 62: Sarasar 7MM sales forecast in second-line MDS ($m), 2007-2016
  - Table 63: TheraCIM: Key historical events
  - Table 64: Ongoing clinical trials involving TheraCIM, 2007
  - Table 65: Forecasting assumptions for TheraCIM in the seven major pharmaceutical markets, 2007
  - Table 66: TheraCIM 7MM sales forecast in first-line glioma ($m), 2007-2016
  - Table 67: Xinlay: Key historical events
  - Table 68: Ongoing clinical trials involving Xinlay, 2007
  - Table 69: Meta-analysis of pooled data from two randomized Phase III trials (M96-594 and M00-211) of Xinlay versus placebo in metastatic HRPC
  - Table 70: Forecasting assumptions for Xinlay in the seven major pharmaceutical markets, 2007
  - Table 71: Xinlay 7MM sales forecast in first-line metastatic HRPC ($m), 2007-2016
  - Table 72: Zalutumumab: Key historical events
  - Table 73: Ongoing clinical trials involving zalutumumab, 2007
  - Table 74: Phase I/II study results of zalutumumab in recurrent SCCHN
  - Table 75: Forecasting assumptions for zalutumumab in the seven major pharmaceutical markets, 2007
  - Table 76: Zalutumumab 7MM sales forecast in first/second-line SCCHN ($m), 2007-2016
  - Table 77: Zarnestra: Key historical events
  - Table 78: Ongoing clinical trials involving Zarnestra, 2007
  - Table 79: Phase I/II study of Zarnestra in combination with chemotherapy in newly diagnosed AML or high-risk MDS patients
  - Table 80: Phase II results for Zarnestra in elderly, previously untreated poor-risk AML patients who were not suitable for chemotherapy
  - Table 81: Phase II results of Zarnestra monotherapy in relapsed/refractory aggressive NHL, 2006
  - Table 82: Phase II study results of Zarnestra in juvenile myelomonocytic leukemia (JMML), 2005
  - Table 83: Phase I/II trial involving Nexavar, Tarceva, Torisel and Zarnestra, 2006
  - Table 84: Phase III trial results of Zarnestra in pancreatic cancer
  - Table 85: Phase III trial results of Zarnestra in CRC
  - Table 86: Forecasting assumptions for Zarnestra in the seven major pharmaceutical markets, 2007
  - Table 87: Zarnestra 7MM sales forecasts in first-line elderly AML ($m), 2007-2016
  - Table 88: Late-phase pipeline multi-targeted inhibitors, 2007
  - Table 89: Phase II pipeline multi-targeted inhibitors, 2007
  - Table 90: Phase I pipeline multi-targeted inhibitors, 2007
  - Table 91: Forecasting assumptions for late-phase multi-targeted inhibitors in the seven major pharmaceutical markets, 2007 (1 of 2)
  - Table 92: Forecasting assumptions for late-phase multi-targeted inhibitors in the seven major pharmaceutical markets, 2007 (2 of 2)
  - Table 93: Gleevec: Key facts
  - Table 94: Tasigna: Key historical events
  - Table 95: Ongoing clinical trials involving Tasigna, 2007
  - Table 96: Trial design and clinical outcomes for a small patient subgroup from the ENACT trial
  - Table 97: Phase II results for Tasigna in Gleevec-resistant or intolerant patients with CML in chronic phase
  - Table 98: Phase II results for Tasigna in Gleevec-resistant or intolerant patients with CML in accelerated phase
  - Table 99: Phase II results for Tasigna in Gleevec-resistant or intolerant patients with CML in blast crisis phase or relapsed/refractory Ph+ ALL
  - Table 100: Phase II results for Tasigna in hypereosinophilic syndrome (HES)
  - Table 101: Phase II results for Tasigna in systemic mastocytosis
  - Table 102: Phase II results for Tasigna in Gleevec and Sprycel-resistant or intolerant patients with CML in all stages of the disease
  - Table 103: Phase I results for Tasigna with or without Gleevec in Gleevec-resistant GIST
  - Table 104: Forecasting assumptions for Tasigna in the seven major pharmaceutical markets, 2007
  - Table 105: Tasigna sales forecast in Gleevec-refractory CML and third-line GIST ($m), 2007-2016
  - Table 106: Axitinib: Key historical events
  - Table 107: Ongoing clinical trials involving axitinib, 2007
  - Table 108: Phase II results for axitinib in thyroid cancer
  - Table 109: Phase II results for axitinib in Nexavar-refractory mRCC
  - Table 110: Phase II results for axitinib in relapsed NSCLC
  - Table 111: Forecasting assumptions for axitinib in the seven major pharmaceutical markets, 2007
  - Table 112: Axitinib 7MM sales forecast in first-line pancreatic cancer and second-line thyroid cancer ($m), 2007-2016
  - Table 113: Ceflatonin: Key historical events
  - Table 114: Ongoing clinical trials involving Ceflatonin, 2007
  - Table 115: Interim data for Ceflatonin monotherapy in patients with Gleevec-refractory CML harboring the T315I Bcr-Abl point mutation
  - Table 116: Phase II trial outline for Ceflatonin plus Gleevec in Gleevec-refractory patients
  - Table 117: Interim data for Ceflatonin in combination with Gleevec in patients with Gleevec-refractory CML
  - Table 118: Forecasting assumptions for Ceflatonin in the seven major pharmaceutical markets, 2007
  - Table 119: Ceflatonin 7MM sales forecast in Gleevec-resistant CML ($m), 2007-2016
  - Table 120: Enzastaurin: Key historical events
  - Table 121: Ongoing clinical trials involving enzastaurin, 2007
  - Table 122: Phase II results of enzastaurin in relapsed DLBCL
  - Table 123: Phase II results of enzastaurin in relapsed MCL
  - Table 124: Phase II results of enzastaurin in second/third-line NSCLC
  - Table 125: Forecasting assumptions for enzastaurin in the seven major pharmaceutical markets, 2007
  - Table 126: Enzastaurin 7MM sales forecast as a maintenance therapy in DLBCL ($m), 2007-2016
  - Table 127: Lestaurtinib: Key historical events
  - Table 128: Ongoing clinical trial involving lestaurtinib, 2007
  - Table 129: Interim Phase II/III results of lestaurtinib and chemotherapy in patients with relapsed AML harboring Flt-3 activating mutations
  - Table 130: Forecasting assumptions for lestaurtinib in the seven major pharmaceutical markets, 2007
  - Table 131: Lestaurtinib 7MM sales forecast in second-line AML ($m), 2007-2016
  - Table 132: Zactima' s multiple anticancer targets
  - Table 133: Zactima: Key historical events
  - Table 134: Ongoing clinical trials involving Zactima, 2007
  - Table 135: Phase II results for Zactima monotherapy in metastatic hereditary medullary thyroid cancer
  - Table 136: Phase II results for Zactima plus chemotherapy in first-line NSCLC
  - Table 137: Phase II results for Zactima plus Taxotere in second-line NSCLC
  - Table 138: Phase I results for Zactima plus Alimta in second-line NSCLC
  - Table 139: Forecasting assumptions for Zactima in the seven major pharmaceutical markets, 2007
  - Table 140: Zactima 7MM sales forecast in NSCLC ($m), 2007-2016
  - Table 141: Late-phase pipeline cell cycle and apoptosis targeted agents, 2007
  - Table 142: Phase II pipeline cell cycle and apoptosis targeted agents, 2007
  - Table 143: Phase I pipeline cell cycle and apoptosis targeted agents, 2007
  - Table 144: Forecasting assumptions for late-phase cell cycle and apoptosis targeted agents in the seven major pharmaceutical markets, 2007
  - Table 145: Velcade: Key facts
  - Table 146: Alvocidib: Key historical events
  - Table 147: Ongoing clinical trials involving alvocidib, 2007
  - Table 148: Genasense: Key historical events
  - Table 149: Forecasting assumptions for Genasense in the seven major pharmaceutical markets, 2007
  - Table 150: Genasense 7MM sales forecast in first-line elderly AML and first-line metastatic melanoma ($m), 2007-2016
  - Table 151: Phenoxodiol: Key historical events
  - Table 152: Ongoing clinical trials involving phenoxodiol, 2007
  - Table 153: Forecasting assumptions for phenoxodiol in the seven major pharmaceutical markets, 2007
  - Table 154: Phenoxodiol 7MM sales forecast in third-line ovarian cancer ($m), 2007-2016
  - Table 155: Late-phase pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Table 156: Phase II pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Table 157: Phase I pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Table 158: Forecasting assumptions for late-phase immunomodulatory and immunoconjugated therapeutics in the seven major pharmaceutical markets, 2007 (1 of 2)
  - Table 159: Forecasting assumptions for late-phase immunomodulatory and immunoconjugated therapeutics in the seven major pharmaceutical markets, 2007 (2 of 2)
  - Table 160: Approved indications for Rituxan in the US and EU, 2006
  - Table 161: Rituxan: Key facts
  - Table 162: Galiximab: Key historical events
  - Table 163: Ongoing clinical trial involving galiximab, 2007
  - Table 164: Phase II study of galiximab in combination with Rituxan in relapsed/refractory follicular NHL
  - Table 165: Retrospective comparison of galiximab plus Rituxan with Rituxan monotherapy in relapsed/refractory follicular NHL
  - Table 166: Forecasting assumptions for galiximab in the seven major pharmaceutical markets, 2007
  - Table 167: Galiximab 7MM sales forecast in follicular NHL ($m), 2007-2016
  - Table 168: Lumiliximab: Key historical events
  - Table 169: Ongoing clinical trial involving lumiliximab, 2007
  - Table 170: Comparison of results from a Phase I/II study of lumiliximab in combination with FCR in relapsed/refractory CLL
  - Table 171: Biogen Idec' s Cluster of Differentiation (CD) targeted drugs, 2007
  - Table 172: Forecasting assumptions for lumiliximab in the seven major pharmaceutical markets, 2007
  - Table 173: Lumiliximab 7MM sales forecast in relapsed/refractory CLL ($m), 2007-2016
  - Table 174: Ofatumumab: Key historical events
  - Table 175: Ongoing clinical trial involving ofatumumab, 2007
  - Table 176: Phase I/II results of ofatumumab in relapsed/refractory CLL
  - Table 177: Interim Phase I/II results of ofatumumab in relapsed/refractory follicular NHL
  - Table 178: Phase I/II adverse events data from ofatumumab in relapsed/refractory follicular NHL
  - Table 179: GlaxoSmithKline' s marketed oncology portfolio, 2007
  - Table 180: Forecasting assumptions for ofatumumab in the seven major pharmaceutical markets, 2007
  - Table 181: Ofatumumab 7MM sales forecast in relapsed/refractory CLL and second-line follicular NHL ($m), 2007-2016
  - Table 182: Proxinium: Key historical events
  - Table 183: Ongoing clinical trials involving Proxinium, 2007
  - Table 184: Forecasting assumptions for Proxinium in the seven major pharmaceutical markets, 2007
  - Table 185: Proxinium 7MM sales forecast in second-line SCCHN ($m), 2007-2016
  - Table 186: Rencarex: Key historical events
  - Table 187: Ongoing clinical trials involving Rencarex, 2007
  - Table 188: Phase I/II study of Rencarex plus IFN in metastatic RCC
  - Table 189: Ongoing Phase III trials in the adjuvant RCC setting
  - Table 190: Forecasting assumptions for Rencarex in the seven major pharmaceutical markets, 2007
  - Table 191: Rencarex 7MM sales forecast in adjuvant RCC ($m), 2007-2016
  - Table 192: Zanolimumab: Key historical events
  - Table 193: Ongoing clinical trial involving zanolimumab, 2007
  - Table 194: Phase II results of zanolimumab in mycosis fungoides CTCL
  - Table 195: Interim Phase II results of zanolimumab in PTCL patients
  - Table 196: Forecasting assumptions for zanolimumab in the seven major pharmaceutical markets, 2007
  - Table 197: Zanolimumab 7MM sales forecast in relapsed CTCL ($m), 2007-2016
  - Table 198: Zolinza: Key facts
  - Table 199: Phase II pipeline epigenetic modulators, 2007
  - Table 200: Phase I pipeline epigenetic modulators, 2007
  - Table 201: Datamonitor drug assessment parameters
  - Table 202: Abbreviations used in Pipeline Insight: Molecular Targeted Cancer Therapies
- List of Figures
  - Figure 1: Pipeline molecular targeted therapies by development phase and class of drug, 2007
  - Figure 2: Pipeline molecular targeted therapies by class of drug, 2007
  - Figure 3: Pipeline molecular targeted therapies by development phase, 2007
  - Figure 4: Angiogenesis inhibitors by developmental phase, 2007
  - Figure 5: Single-target signal transduction inhibitors by developmental phase, 2007
  - Figure 6: Multi-targeted inhibitors by developmental phase, 2007
  - Figure 7: Cell cycle and apoptosis targeted agents by developmental phase, 2007
  - Figure 8: Immunomodulatory and immunoconjugated therapeutics by developmental phase, 2007
  - Figure 9: Epigenetic modulators by developmental phase, 2007
  - Figure 10: Pipeline molecular targeted therapies by indication, 2007
  - Figure 11: Pipeline molecular targeted therapies by hematological malignancy, 2007
  - Figure 12: Potential anticancer molecular targets being exploited by four or more candidates in the clinical development pipeline, 2007
  - Figure 13: Molecular targeted therapies product pipeline by type of company, 2007
  - Figure 14: Segmentation of companies according to number of products in the MTT pipeline, 2007
  - Figure 15: Companies with MTT candidates in late-phase development, 2007
  - Figure 16: Companies with four or more candidates in the molecular targeted therapies pipeline, 2007
  - Figure 17: Pipeline angiogenesis inhibitors sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 18: Pipeline single-target signal transduction inhibitors sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 19: Pipeline multi-targeted inhibitors sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 20: Pipeline cell cycle and apoptosis targeted agents sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 21: Pipeline immunomodulatory and immunoconjugated therapeutics sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 22: Clinical and commercial attractiveness of pipeline angiogenesis inhibitors, 2007
  - Figure 23: Clinical and commercial attractiveness of pipeline single-target signal transduction inhibitors, 2007
  - Figure 24: Clinical and commercial attractiveness of pipeline multi-targeted inhibitors, 2007
  - Figure 25: Clinical and commercial attractiveness of pipeline cell cycle and apoptosis targeted agents, 2007
  - Figure 26: Clinical and commercial attractiveness of pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Figure 27: The process of tumor angiogenesis
  - Figure 28: Clinical and commercial attractiveness of pipeline angiogenesis inhibitors, 2007
  - Figure 29: Pipeline angiogenesis inhibitors sales forecasts in the seven major markets ($m), 2007-2016
  - Figure 30: Interim Phase II results of aflibercept in ovarian cancer
  - Figure 31: Aflibercept 7MM sales forecast in second-line ovarian cancer, second-line NSCLC and second-line HRPC ($m), 2007-2016
  - Figure 32: Clinical and commercial attractiveness of aflibercept, 2007
  - Figure 33: Pazopanib' s mode of action
  - Figure 34: Phase III study design for pazopanib monotherapy in second-line RCC
  - Figure 35: Phase II study design for pazopanib monotherapy in second-line RCC
  - Figure 36: Phase II study design for pazopanib monotherapy in relapsed soft tissue sarcoma
  - Figure 37: Phase II study design for pazopanib monotherapy in high-risk relapsed ovarian cancer
  - Figure 38: Pazopanib 7MM sales forecast in first/second-line RCC and second-line Her2+ breast cancer ($m), 2007-2016
  - Figure 39: Clinical and commercial attractiveness of pazopanib, 2007
  - Figure 40: Recentin (cediranib; AZD2171) mode of action
  - Figure 41: Phase I interim results for Recentin in second-line CRC
  - Figure 42: HORIZON II and HORIZON III clinical trials designs involving Recentin in first-line CRC
  - Figure 43: Recentin 7MM sales forecast in first-line NSCLC, first-line CRC and recurrent/ progressive glioma ($m), 2007-2016
  - Figure 44: Clinical and commercial attractiveness of Recentin, 2007
  - Figure 45: Clinical and commercial attractiveness of pipeline single-target signal transduction inhibitors, 2007
  - Figure 46: Pipeline single-target signal transduction inhibitors sales forecasts in the seven major markets ($m), 2007-2016
  - Figure 47: Phase II results of Certican monotherapy in breast cancer
  - Figure 48: Phase II results of Certican monotherapy in NSCLC
  - Figure 49: Certican 7MM sales forecast in second-line NET, second-line RCC, salvage therapy CRC and second-line GIST ($m), 2007-2016
  - Figure 50: Clinical and commercial attractiveness of Certican, 2007
  - Figure 51: Sarasar 7MM sales forecast in second-line MDS ($m), 2007-2016
  - Figure 52: Clinical and commercial attractiveness of Sarasar, 2007
  - Figure 53: Phase II trial results for TheraCIM in pediatric glioma
  - Figure 54: TheraCIM 7MM sales forecast in first-line glioma ($m), 2007-2016
  - Figure 55: Clinical and commercial attractiveness of TheraCIM, 2007
  - Figure 56: Clinical trial design for the recently initiated Phase III trial involving Xinlay in HRPC
  - Figure 57: Xinlay 7MM sales forecast in first-line metastatic HRPC ($m), 2007-2016
  - Figure 58: Clinical and commercial attractiveness of Xinlay, 2007
  - Figure 59: Types of monoclonal antibodies
  - Figure 60: Zalutumumab 7MM sales forecast in first/second-line SCCHN ($m), 2007-2016
  - Figure 61: Clinical and commercial attractiveness of zalutumumab, 2007
  - Figure 62: Phase I/II trial design of Zarnestra in combination with chemotherapy in newly diagnosed AML or high-risk MDS patients
  - Figure 63: Zarnestra 7MM sales forecasts in first-line elderly AML ($m), 2007-2016
  - Figure 64: Clinical and commercial attractiveness of Zarnestra, 2007
  - Figure 65: Clinical and commercial attractiveness of pipeline multi-targeted inhibitors, 2007
  - Figure 66: Pipeline multi-targeted inhibitors sales forecasts ($m), 2007-2016
  - Figure 67: Phase I study outline for Tasigna with or without Gleevec in Gleevec-resistant GIST
  - Figure 68: Tasigna sales forecast in Gleevec-refractory CML and third-line GIST ($m), 2007-2016
  - Figure 69: Clinical and commercial attractiveness of Tasigna, 2007
  - Figure 70: Phase II results for axitinib plus Gemzar in first-line pancreatic cancer
  - Figure 71: Randomized Phase II study results for axitinib plus Taxotere in first-line metastatic breast cancer
  - Figure 72: Axitinib 7MM sales forecast in first-line pancreatic cancer and second-line thyroid cancer ($m), 2007-2016
  - Figure 73: Clinical and commercial attractiveness of axitinib, 2007
  - Figure 74: Phase II/III trial for Ceflatonin in Gleevec-refractory CML
  - Figure 75: Ceflatonin 7MM sales forecast in Gleevec-resistant CML ($m), 2007-2016
  - Figure 76: Clinical and commercial attractiveness of Ceflatonin, 2007
  - Figure 77: Enzastaurin 7MM sales forecast as a maintenance therapy in DLBCL ($m), 2007-2016
  - Figure 78: Clinical and commercial attractiveness of enzastaurin, 2007
  - Figure 79: Lestaurtinib 7MM sales forecast in second-line AML ($m), 2007-2016
  - Figure 80: Clinical and commercial attractiveness of lestaurtinib, 2007
  - Figure 81: Phase II results for maintenance Zactima in SCLC
  - Figure 82: Zactima 7MM sales forecast in NSCLC ($m), 2007-2016
  - Figure 83: Clinical and commercial attractiveness of Zactima, 2007
  - Figure 84: Clinical and commercial attractiveness of pipeline cell cycle and apoptosis targeted agents, 2007
  - Figure 85: Pipeline cell cycle and apoptosis targeted agents sales forecasts ($m), 2007-2016
  - Figure 86: Phase I results for alvocidib monotherapy in CLL
  - Figure 87: Phase II results for alvocidib plus chemotherapy in acute leukemias
  - Figure 88: Genasense 7MM sales forecast in first-line elderly AML and first-line metastatic melanoma ($m), 2007-2016
  - Figure 89: Clinical and commercial attractiveness of Genasense, 2007
  - Figure 90: Phase II results for phenoxodiol plus chemotherapy in resistant/refractory ovarian cancer
  - Figure 91: Phenoxodiol 7MM sales forecast in third-line ovarian cancer ($m), 2007-2016
  - Figure 92: Clinical and commercial attractiveness of phenoxodiol, 2007
  - Figure 93: Clinical and commercial attractiveness of pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Figure 94: Pipeline immunomodulatory and immunoconjugated therapeutics sales forecasts ($m), 2007-2016
  - Figure 95: Galiximab 7MM sales forecast in follicular NHL ($m), 2007-2016
  - Figure 96: Clinical and commercial attractiveness of galiximab, 2007
  - Figure 97: Phase I/II study design for lumiliximab in combination with FCR in relapsed/refractory CLL
  - Figure 98: Lumiliximab 7MM sales forecast in relapsed/refractory CLL ($m), 2007-2016
  - Figure 99: Clinical and commercial attractiveness of lumiliximab, 2007
  - Figure 100: Phase III study design for ofatumumab in patients with CLL refractory to both fludarabine and Campath
  - Figure 101: Phase III study design for ofatumumab in Rituxan-refractory follicular NHL
  - Figure 102: Ofatumumab 7MM sales forecast in relapsed/refractory CLL and second-line follicular NHL ($m), 2007-2016
  - Figure 103: Clinical and commercial attractiveness of ofatumumab, 2007
  - Figure 104: Phase I results for Proxinium in advanced SCCHN
  - Figure 105: Phase I/II results for Vicinium in superficial TCC of the bladder
  - Figure 106: Proxinium 7MM sales forecast in second-line SCCHN ($m), 2007-2016
  - Figure 107: Clinical and commercial attractiveness of Proxinium, 2007
  - Figure 108: Rencarex induced ADCC
  - Figure 109: Phase II study design for Rencarex monotherapy in advanced RCC
  - Figure 110: Rencarex Phase II results: median survival
  - Figure 111: Phase I/II study design for Rencarex plus IFN in metastatic RCC
  - Figure 112: Rencarex 7MM sales forecast in adjuvant RCC ($m), 2007-2016
  - Figure 113: Clinical and commercial attractiveness of Rencarex, 2007
  - Figure 114: Phase III study design for zanolimumab in CTCL
  - Figure 115: Preliminary results for the first stage of the Phase III study for zanolimumab in CTCL
  - Figure 116: Zanolimumab 7MM sales forecast in relapsed CTCL ($m), 2007-2016
  - Figure 117: Clinical and commercial attractiveness of zanolimumab, 2007
  - Figure 118: Datamonitor drug assessment summary of pipeline molecular targeted therapies in development for hematological malignancies, 2007

Pipeline Insight: Molecular Targeted Cancer Therapies - Can anything else revolutionize the market?

Table of Contents